The combination therapy was also validated in cetuximab-resistant HNSCC patient-derived xenograft models, where it led to a notable delay in tumor growth and decreased activation of MAPK, AKT, and DRP1 signaling, consistent with in vitro findings. Here, AKT1 is linked to neoplasm.